Nantahala Capital Management LLC Takes $6.05 Million Position in Lexeo Therapeutics, Inc. $LXEO

Key Points

• Nantahala Capital Management acquired 1.3 million Lexeo Therapeutics shares worth approximately $6.05 million, giving it a 1.58% stake. Institutional investors and hedge funds collectively own 60.67% of the company.
• Analyst sentiment remains broadly positive, with an average rating of “Buy” and an average price target of $18.75, although JPMorgan lowered its target to $9.00 and some firms issued bearish ratings.
• LXEO shares opened at $4.86, near the lower end of their 52-week range, while Lexeo reported a quarterly loss of $0.30 per share—slightly below the $0.29 consensus estimate. Insiders also sold shares to cover tax obligations related to equity vesting.

Nantahala Capital Management LLC bought a new position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 1,300,000 shares of the company's stock, valued at approximately $6,051,500. Nantahala Capital Management LLC owned 1.58% of Lexeo Therapeutics at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Avoro Capital Advisors LLC bought a new stake in Lexeo Therapeutics in the 2nd quarter valued at $6,932,175. Bank of America Corp DE bought a new position in Lexeo Therapeutics during the 2nd quarter worth $2,282,000. Jupiter Topco LLC bought a new position in Lexeo Therapeutics during the 2nd quarter worth $18,409,000. ADAR1 Capital Management LLC bought a new position in Lexeo Therapeutics during the 2nd quarter worth $7,289,000. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Lexeo Therapeutics during the second quarter worth $86,000. 60.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

LXEO has been the subject of a number of recent research reports. JPMorgan Chase & Co. reduced their target price on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an "overweight" rating for the company in a research report on Thursday, June 25th. Weiss Ratings raised shares of Lexeo Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, August 13th. Wall Street Zen cut shares of Lexeo Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Saturday, August 15th. Finally, Chardan Capital raised shares of Lexeo Therapeutics to a "strong-buy" rating in a report on Tuesday, July 28th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $18.75.

Lexeo Therapeutics Price Performance

Shares of LXEO opened at $4.86 on Friday. The company has a market capitalization of $398.76 million, a price-to-earnings ratio of -4.23 and a beta of 1.46. Lexeo Therapeutics, Inc. has a 1 year low of $3.99 and a 1 year high of $10.99. The business has a 50-day moving average of $4.74 and a 200-day moving average of $5.46.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.01). As a group, sell-side analysts anticipate that Lexeo Therapeutics, Inc. will post -1.18 EPS for the current year.

Insider Activity at Lexeo Therapeutics

In other Lexeo Therapeutics news, insider Narinder Pal Bhalla sold 22,306 shares of the firm's stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $4.42, for a total value of $98,592.52. Following the completion of the sale, the insider owned 82,194 shares of the company's stock, valued at approximately $363,297.48. This trade represents a 21.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Richard Nolan Townsend sold 25,947 shares of Lexeo Therapeutics stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $4.48, for a total transaction of $116,242.56. Following the transaction, the chief executive officer owned 377,817 shares of the company's stock, valued at $1,692,620.16. This represents a 6.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 66,326 shares of company stock worth $299,817. Corporate insiders own 2.00% of the company's stock.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.

Want to see what other hedge funds are holding LXEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source